Monte Rosa Therapeutics

GLUENasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.342 B

$15.88 +1.08%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$38.6M

Loss-making

Shares outstanding

85,313,401

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#40SL ScienceSLBT$1.50B
#41Vir BiotechnologyVIR$1.49B
#42Monte Rosa TherapeuticsGLUE$1.34B
#43NovavaxNVAX$1.31B
#44Inhibrx BiosciencesINBX$1.30B

Where these numbers come from

Share counts and financials for Monte Rosa Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.